Company Filing History:
Years Active: 1999-2002
Title: The Innovations of Jeffrey S. Culp
Introduction
Jeffrey S. Culp is a prominent inventor based in Collegeville, Pennsylvania. With a total of five patents to his name, he has made significant contributions to the field of biotechnology, particularly in the development of therapeutic and diagnostic methods. His work focuses on innovative polypeptides and polynucleotides that have the potential to impact medical science.
Latest Patents
Among his most recent inventions, Jeffrey has patented methods related to Human Urotensin II. This includes the Human Urotensin II polypeptides and polynucleotides, as well as techniques for producing these substances through recombinant methods. His patents also detail the usage of Human Urotensin II in therapeutic applications and diagnostic assays. Another of his notable patents involves methods for screening both agonists and antagonists of the HDPXU17 receptor, covering the HDPXU17 polypeptides and polynucleotides. This invention elucidates approaches for assessing interactions between the HDPXU17 receptor and its ligands, including desoxyadenosine triphosphate (dATP), deoxyadenosine monophosphate (dAMP), and uridine triphosphate (UTP).
Career Highlights
Jeffrey S. Culp is currently associated with the SmithKline Beecham Corporation, a significant player in the pharmaceutical industry. His role at the company has allowed him to explore and expand upon his innovations, driving advancements in biotech research and development.
Collaborations
Throughout his career, Jeffrey has worked alongside esteemed colleagues, including Catherine E. Ellis and Dean E. McNulty. These collaborations have played a vital role in nurturing an environment of innovation and discovery, leading to the successful development of their respective projects.
Conclusion
Jeffrey S. Culp's contributions to biotechnology through his patents and collaborations exemplify the spirit of innovation within the field. With each invention, he continues to pave the way for advancements that could enhance therapeutic strategies and diagnostic capabilities, marking him as a noteworthy figure in contemporary science.